Overview

The Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF Treatment

Status:
Unknown status
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
To evaluate whether treatment with Estradiol supplementation during the luteal phase improves IVF outcomes Patients undergoing IVF treatment with controlled ovarian hyperstimulation using a GnRH analog will receive 4 mg estradiol valerate in the luteal phase.Patient's followup will include E2 progesterone and BHCG 14 days after embryo transfer and vaginal ultrasound on day 21 and 28 after embryo transfer
Phase:
Phase 1
Details
Lead Sponsor:
Assaf-Harofeh Medical Center
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate